img_0788_edited.jpg

PIPELINES

6.jpg

Unique characteristics of the CX series

The CX series, a key technology at Cenyx Biotech, is a nanozyme based on CX synthetic platform technology. These nanocompounds can provide a variety of functions in nanozyme reactions, and it is being developed as the world's first nanozyme technology to be used in clinical applications.

Pipeline Overview

Project

Target conditions or Uses

Discovery

Target

Rx

Preclinical

Phase 1

Phase 2

Phase 3

Nanozyme
(CX213)

TD1

Subarachnoid hemorrhage**

Target disease 2

Target disease 3

Target disease 4

Target disease 5

Target disease 6

Target disease 7

Target disease 8

Target disease 9

Target disease 10

Target disease 11

Nanocontrast

Target disease 12

Nanozyme
complex

Target disease 13

Target disease 14

Target disease 15

Nanobomb

Target disease 16

​* The details of substance names and indications are in confidence.

please contact office for details.